23 1 21. https://who.int/news-room/fact-sheets/ detail/palliative-care (20 August 2021, date last accessed). 22. https://mascc.org/mascc-strategic-plan (20 August 2021, date last accessed). 23. Jordan K, Aapro M, Kaasa S et al. A. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol 2018;29:36-43. 24. Kaasa S, Loge JH, Aapro M et al. Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol 2018;19:e588-e653. 25. Vinches M, Neven A, Fenwarth L et al. Clinical research in cancer palliative care: a metaresearch analysis. BMJ Support Palliat Care 2020;10:249-58. 26. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol 2014;740:36478. 27. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003;4:889-901. 28. Sastry J., Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr. Hematol. Oncol 2005;22:441-5. 29. Arany I., Safirstein RL. Cisplatin nephrotoxicity. Semin. Nephrol 2003;23:460-4. 30. Madias NE, Harrington JT. Platinum nephrotoxicity. Am. J. Med 1978;65:30714. 31. Goldstein RS, Mayor GH. Minireview. The nephrotoxicity of cisplatin. Life Sci 1983;32:685-90. 32. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010;2:2490-518. 33. Volarevic V, Djokovic B, Jankovic MG et al. Molecular mechanisms of cisplatininduced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci 2019;26:25. 34. Bellomo R, Ronco C, Kellum JA et al. Acute renal failure- definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12. 35. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31. 36. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2(Suppl 1):1-138. 37. https://www.Cancer Statistics Review, 1975-2015- SEER Statistics (20 August 2021, date last accessed). 38. Mehanna H, West CM, Nutting C, Paleri V. Head and neck cancer--Part 2: Treatment and prognostic factors. BMJ 2010;341:c4690. 39. Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8. 40. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
RkJQdWJsaXNoZXIy MjY0ODMw